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For a decade, coronary computed tomographic angiography (CCTA) has been used as a promising noninvasive modality for the
assessment of coronary artery disease (CAD) as well as cardiovascular risks. CCTA can provide more information incorporating
the presence, extent, and severity of CAD; coronary plaque burden; and characteristics that highly correlate with those on invasive
coronary angiography. Moreover, recent techniques of CCTA allow assessing hemodynamic significance of CAD. CCTA may be
potentially used as a substitute for other invasive or noninvasivemodalities.This review summarizes risk stratification by anatomical
and hemodynamic information of CAD, coronary plaque characteristics, and burden observed on CCTA.
1. Introduction
Coronary artery disease (CAD) remains the leading cause of
high morbidity and mortality in the world. Recent advanced
technologies allow estimating future cardiovascular risks
with correction of numerous CAD variables using several
invasive or noninvasive modalities among patients with
suspected CAD. These CAD variables are provided by mul-
tiple approaches such as anatomical information including
the presence, extent, and severity of CAD, hemodynamic
information, and coronary plaque vulnerability, which all
have been widely used for risk discrimination and stratifi-
cation. The recent FAME trials raised an important ques-
tion regarding guiding medical management for patients
who would receive benefits from revascularization based
on hemodynamic or anatomical significance of CAD [1, 2].
Also, the PROSPECT study demonstrated the importance
to investigate coronary plaque morphology including the
severity, volume, and vulnerability provided by intravascular
ultrasound (IVUS) in predicting future cardiovascular risks
[3]. Since these CAD features improve the risk stratification
and guide medical management, it is important to under-
stand how to accurately select patients or examinations in
a clinical setting. Another potential problem may be that
most of these prospective studies were examined by invasive
coronary angiography (ICA), which is the reference standard
to identify the anatomical and functional significant CAD.
Although diagnostic and prognostic values of ICA have been
established for decades, inadequate performance of ICA can
be a potential risk [4]. Thus, to avoid unnecessary ICAs,
the prediction and stratification of the risk by noninvasive
modalities should be considered among subjects with sus-
pected CAD.
Coronary computed tomographic angiography (CCTA)
has been widely used as a noninvasive modality for the
measurement of CAD presence and severity [5–7] and risk
stratification [8–10] among subjects with suspected CAD.
Because of the high spatial and temporal resolution, CCTA
provides anatomical information, coronary plaque burden,
and coronary plaquemorphology, which cannot be visualized
by ICA. In addition to this benefit, a recent advanced tech-
nology of CCTA may also allow identifying hemodynamic
significance of CAD. This review summarizes the utility of
CCTA by the standpoints in assessing anatomical and hemo-
dynamic variables while also detecting plaque morphology
and burden for risk stratification.
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2. Anatomical Assessment of Coronary
Artery Disease by Coronary Computed
Tomographic Angiography
ICA has been a gold standard to identify anatomical sig-
nificance of CAD for many years. A recent large study by
the American College of Cardiology National Cardiovascular
Data Registry [11], however, demonstrated that nearly two-
thirds of subjects undergoing ICA did not have obstructive
CAD. According to the recent appropriate use criteria [12],
candidates for ICA should be carefully selected and should
have obstructive CAD among symptomatic patients or possi-
bly obstructive stenosis of the leftmain among asymptomatic
patients.
For a decade, numerous investigators have demonstrated
the diagnostic utility of CCTA to identify the stenosis severity
of CAD. Several multicenter studies have demonstrated
the high diagnostic accuracy of CCTA [5–7]. Budoff et al.
examined the diagnostic performance of CCTA compared
to invasive ICA [5]. In this prospective ACCURACY study
of 230 patients, CCTA demonstrated excellent diagnostic
performance, particularly high sensitivity, andNPVwith 95%
and 99%, respectively. Because of high temporal and spatial
resolutions of CCTA, CCTAhas been a robust diagnostic tool
to identify the presence, extent, and severity of CAD and is
unlikely to miss high risk CAD.
3. Risk Stratification by
Anatomical Assessment of Coronary
Artery Disease by Coronary Computed
Tomographic Angiography
Numerous previous studies demonstrated the prognostic
utility of CCTA by anatomical assessment including the
presence, extent, and severity of CAD [8–10]. A recent inter-
national multicenter CONFIRM study showed the anatom-
ical stenosis severity of CAD was associated with higher
mortality rate [10]. In this study of 23854 patients without
knownCAD, they observed that patients with nonobstructive
(<50%) and obstructive CAD (≥50%) experienced 1.6- and
2.6-fold greatermortality risk compared to thosewith normal
coronary artery. In addition to the stenosis severity alone, the
extents of coronary stenosis severity in 1-vessel (HR 2.00, 95%
CI 1.43–2.82, 𝑃 < 0.0001), 2-vessel (HR 2.92, 95% CI 2.00–
4.25, 𝑃 < 0.0001), and 3-vessel diseases or left main disease
(HR 3.70, 95% CI 2.58–5.29, 𝑃 < 0.0001) were associated
with greater mortality risk. These results were concordant
with those of previous studies [8, 13]. Also, the mortality
risk was associated with not only obstructive stenosis with
≥50%, but also nonobstructive stenosis with <50%. In 2583
subjects without known CAD and without obstructive CAD
≥50% by coronary CTA, Lin et al. demonstrated that the
presence and extent of nonobstructive CAD were associated
with worsening mortality during 3.1 ± 0.5 years [14]. Diffuse
extended CAD is also associated with mortality. Bittencourt
et al. [15] more recently explored the prognostic value of
CCTA between nonobstructive and obstructive CAD and
nonextensive (≤4 segments) and extensive (>4 segments)
CAD. In this study of 3432 patients during a median of 3.6
years, they observed that the extensive obstructive CAD (HR
3.9, 95% CI 2.2–7.2), extensive nonobstructive CAD (HR 3.1,
95% CI 1.5–6.4), and nonextensive obstructive CAD (HR
3.0, 95% CI 1.3–6.9) were associated with the heightened
cardiovascular events incorporating cardiovascular death or
myocardial infarction. Of interest, subjects with extensive
nonobstructive CAD experienced the greater risk compared
to those with nonextensive obstructive CAD. In this regard,
the presence, severity (both obstructive and nonobstructive),
and extent of CAD provided by anatomical assessment are
notable information for risk discrimination. With respect
to guiding the decision for the medical intervention, CCTA
may also be able to identify patients who would benefit
from revascularization. Min et al. investigated 15223 patients
without knownCADbyperformingCCTAand indicated that
high risk CAD incorporating leftmain disease≥50% stenosis,
≥3 segments with ≥70% stenosis or ≥2 segments with ≥70%
stenosis, and the proximal LAD with ≥70% stenosis is
associated with the benefit of revascularization compared
to nonhigh risk CAD [16]. However, future randomized
prospective studies examining observed variables on CCTA
and its benefit for revascularization are required.
In addition to these high diagnostic and prognostic
values, CCTA may play an important role as a gatekeeper
to avoid inadequate performance of ICA. From the same
international multicenter study, Shaw et al. [4] examined
the impact of CCTA to avoid unnecessary ICA and this
risk among 15207 subjects who underwent CCTA. They
observed that subjects with nonobstructive CAD undergoing
ICA experienced 2.2-fold greater mortality risk compared
to those who did not undergo ICA. By contrast, among
subjects with CAD, ICA performance reduced 39%mortality
risk compared to no ICA. Hence, anatomical assessment
of CAD by CCTA provides not only accurate diagnostic
and prognostic implications, but also the additional notable
benefit of avoiding the unnecessary ICA. Based on this
concept, the ongoing prospective CONSERVE trial has been
currently examined to investigate if CCTA can safely reduce
unnecessary ICA as a gatekeeper.
4. Functional Assessment of Coronary
Artery Disease by Coronary Computed
Tomographic Angiography
Even though CCTA provides the high diagnostic perfor-
mance, the anatomical significant coronary stenosis severity
does not always predict the hemodynamic ischemia of CAD
[17, 18]. Given the recent advanced technology, threemethods
are currently available to estimate functional significance of
CAD by CCTA.
Similar to myocardial perfusion SPECT (MPS), CT per-
fusion (CTP) can evaluate myocardial ischemia induced by
pharmacological stress.The good diagnostic accuracy of CTP
has been shown by numerous previous studies, compared
with MPS [19] and MRI [20]. In a recently multicenter study
of CORE 320, the authors have demonstrated the high diag-
nostic performance of combining CCTA and CTP to identify
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CAD among 381 patients [21]. When compared to the tradi-
tional approach by SPECT and ICA to identify patients with
hemodynamic and anatomical significant CAD, this multi-
center study established that this noninvasive approach using
only CCTA can similarly provide high diagnostic accuracy. A
potential problem of CTP is that it requires pharmacological
administration, additional radiation, and contrast medium
for stress imaging since a perfusion image on both rest
and stress is required for diagnosis. In the CORE 320 study
previously mentioned, the mean required radiation exposure
for CTP was 5.31mSv, while that for CTA was 3.16mSv [21].
In contrast to CTP estimating myocardial perfusion
caused by the limited coronary blood flow across the stenosis
on stress and rest, transluminal contrast attenuation gradient
(TAG) can identify lesions-specific ischemia. TAG measures
a drop in contrast medium in the coronary vessel corre-
sponding to the coronary blood flowmeasured using manual
or semiautomated techniques for identifying lesion-specific
ischemia. The greatest advantage of this measurement is that
there is no requirement for any additional contrast medium,
radiation, or image acquisition compared to CTP. Several
studies have examined the relation of TAG to anatomic or
hemodynamic significant CAD to date. Choi et al. investi-
gated the diagnostic accuracy of TAG compared to the steno-
sis severity by invasive ICA among 126 patients undergoing
64-slice CCTA [22]. They observed that increased TAG was
consistently associated with stenosis severity. In addition, the
combined TAG and CCTA stenosis improved classification
of coronary stenosis compared to CCTA alone (area under
the curve [AUC]: 0.951 versus 0.932, 𝑃 = 0.0001), especially
for calcified lesions (AUC: 0.880 versus 0.825, 𝑃 = 0.0001).
The relation of TAG to functional severity of CADby invasive
FFR was also examined by a few previous studies [23, 24].
Wong and colleagues have demonstrated that TAG provided
high sensitivity, specificity, PPV, and NPV (77%, 74%, 67%,
and 86%, resp.) in predicting lesion-specific ischemia by
invasive FFR among 54 patients undergoing 320-slice CCTA
[23]. Also, the combined TAG and CCTA improved the
diagnostic accuracy in predicting functional ischemia (AUC;
0.88, 95% CI 0.81–0.96, 𝑃 < 0.001). Another study by Yoon
et al. explored the diagnostic accuracy of TAG and FFRCT
compared to invasive FFR among 53 patients undergoing 64-
slice CCTA [24]. In this study, TAG demonstrated a modest
association with invasive FFR (𝛾 = 0.379, 𝑃 < 0.001) with
a sensitivity, specificity, PPV, and NPV of 38%, 88%, 67%,
69%, respectively. A potential issue is that TAG only assesses
a contrast attenuation cooperating in the delay of coronary
flow across the stenotic lesion in a coronary vessel in the
rest condition. Based on these limited numbers of previous
studies, the severity of TAG is likely to be associated with
anatomical stenosis severity of CAD but may not relate well
to functional ischemia.
A current innovative technology allows assessing frac-
tional flow reserve (FFR) to identify the lesion-specific
ischemia by CCTA (FFRCT). FFRCT is a novel method pro-
vided by an advanced technique to identify lesion-specific
ischemia by invasive FFR and is computed from various
anatomic and physiologic pieces of information as well as
fluid dynamics observed onCCTA [25]. Todate, 3 prospective
studies investigating the diagnostic performance of FFRCT
were examined. DISCOVER-FLOW is the first multicenter
prospective study examining the diagnostic accuracy of
FFRCT in identifying lesion-specific ischemia by invasive FFR
among 103 patients undergoing CCTA and ICA with FFR
[26]. Second, the larger multicenter DeFACTO study exam-
ined the diagnostic accuracy among 252 patients with stable
CAD [27]. Both studies showed 73–87% accuracy, 90–92.6%
sensitivity, and 84–90.4% NPV. Sequent to these studies,
the most recent multicenter NXT study of 254 patients [28]
showed an AUC for FFRCT with greater diagnostic perfor-
mance compared to that of CTA stenosis alone (0.9 versus
0.81, 𝑃 = 0.0008, resp.). The greatest benefit of this novel
method is that it requires no additional contrast, radiation,
image acquisition, or pharmacological stress but provides
high accuracy using only rest CCTA images in identifying
lesion-specific ischemia. Also, compared to TAG, FFRCT is
not likely to be affected by the number of cardiac cycles
needed for acquisition. The potential issue of this technique
might be that it requires 6 hours to calculate FFRCT. However,
the time requirement for assessing FFRCT has been lately
improved using the latest-generation computational fluid
dynamic techniques.
As mentioned previously, CCTA could be a “gatekeeper”
to avoid unnecessary ICA performance. On the other hand,
CCTA paradoxically may raise the incidence of ICA per-
formed compared to other noninvasive modalities. A pro-
spective SPARC study by Hachamovitch et al. [29] investi-
gated the frequency of ICA or revascularization after nonin-
vasive tests including CCTA, SPECT, or PET. They observed
that patients with abnormal findings after each noninvasive
test weremore likely to undergo ICA compared to thosewith-
out abnormal findings. Even after normal/nonobstructive
andmild test findings, however, the finding of CCTA stenosis
resulted in the higher frequency of ICA compared to SPECT
or PET.This potential paradoxical issue may be caused by the
lower specificity of CCTA in identifying anatomical stenosis
severity because of the overestimation of stenosis by visual
assessment. With respect to this issue, a combination of
both anatomical assessment and hemodynamic assessment of
CAD may be a more robust “gatekeeper” by increasing the
incremental diagnostic accuracy while maintaining higher
sensitivity and specificity compared to anatomical assessment
alone.
5. Risk Stratification by
Functional Assessment of Coronary
Artery Disease by Coronary Computed
Tomographic Angiography
Noninvasive hemodynamic assessment such as myocardial
SPECT imaging has been universally considered as a robust
approach for evaluation of the presence and severity of
hemodynamic significant CAD, the future cardiovascular
risk, as well as decision-making for the optimal medical
intervention or revascularization [30, 31]. A multicenter
FAME study reported by Tonino et al. [1] demonstrated that
functional assessment of CAD by invasive FFR was superior
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to anatomical assessment by ICA for risk stratification among
patients with stable CAD. In this study, they guided decision-
making for revisualization based on functional assessment
which improved the MACE risk compared to the anatomical
assessment. As noted earlier, three methods were utilized to
identify hemodynamic significant CAD on CCTA; however,
the utility for risk stratification by these methods has not
yet been investigated to date. The benefit of CCTA is an
allowance to assess functional significance of CAD followed
by anatomical information using only one modality. This
could save time and costs and reduce the potential risk
by inadequate performance of ICA and/or invasive FFR
to clarify evidence of significant ischemia. The utility of
hemodynamic assessment by CCTA for risk stratification and
the decision-making for the optimal medical intervention
warrant further investigation.
6. Assessment of Coronary Plaque Type
and Vulnerability by Coronary Computed
Tomographic Angiography
Since ICA did not display high grade stenosis of coronary
artery with ≥70% among 50% or more patients having
myocardial infarction [32], ICA without obstructive CAD
does not always imply an excellent prognostic value. The
potential mechanism underlying why ICA misses the coro-
nary lesion associated with future cardiovascular events may
be because ICA cannot show the visualization of coronary
plaque type and/or vulnerability associated with plaque rup-
ture beyond stenosis. The coronary plaque with vulnerability
is the so-called vulnerable plaque [33]. In previous pathology
studies, this adverse plaque is more likely to contain large
necrotic cores, a thin-cap fibroatheroma (TCFA), positive
arterial remodeling, and/or spotty calcification, in which all
of compositions are associatedwith cardiovascular events [33,
34]. Previous studies demonstrated that the adverse plaque
can be visualized using invasive modalities such as IVUS and
cardiovascular optical coherence tomography (OCT), and
the adverse plaque assessed by these modalities provides a
good correlation with that observed on CCTA [35–37]. The
findings of the vulnerable plaque onCCTA are represented by
low attenuation plaque (LAP), positive remodeling, or spotty
calcification [38].
Clinical characteristics are essential factors; however, it
is not always accurate to estimate the future cardiovascular
risk. A recent investigation by Bourantas et al. [39] examined
the relationship of clinical and angiographic characteristics to
high risk plaque, defined as plaque with ≥2 high risk features
including TCFA, plaque burden ≥70%, and/orminimal lumi-
nal area ≤4mm2 detected by IVUS. Compared to subjects
with low risk plaques, they observed that those with high
risk plaques experienced higher cardiovascular risk (Hazard
ratio [HR] 2.63, 95% CI 1.62–4.26, 𝑃 < 0.001). Also, high
risk patients possessed a higher Framingham risk score and a
greater extent of CAD by ICA. Nevertheless, baseline clinical
and angiographic characteristics had an only modest impact
to predict high risk patients (AUC for clinical characteristics
versus clinical and angiographic characteristics; 0.55 versus
0.64). Since the conventional CAD risk factors do not always
identify vulnerable plaque, the visualization of the plaque
type or vulnerability on CCTA by modalities should be
required.
7. Risk Stratification by Coronary
Plaque Type and Vulnerability
Whereas numerous studies demonstrated that vulnerable
plaque detected by IVUS/OCT is likely to be observed among
patients with acute coronary syndrome compared to those
with stable angina [40–43], these invasive methods cannot
routinely be allowed to stratify the risk among subjects with
suspected CAD.
There were only a few studies showing the relation of
plaque futures on coronary CT to cardiovascular events to
date [44, 45]. Our group previously examined 1102 symp-
tomatic subjects with nonobstructive coronary artery disease
detected by electron-beamCT and demonstrated that nonob-
structive noncalcified plaque (NCP) or partially calcified
plaque (PCP) inclusive of both noncalcified and calcified
plaque components, as compared to calcified plaque (CP)
alone, imparted a higher prevalence of long-term adverse
clinical outcomes in a follow-up of 78±12months [44]. In this
study, subjects with NCP experienced 7-fold higher incident
mortality compared to those with CP (9.6% versus 1.4%)
and 3-fold higher than those with PCP (9.6% versus 3.3%).
However, the finding included a potential issue with limited
assessment of plaque type by electron-beamCT. Noncalcified
plaque components detected by CCTA include all fibrous,
fibro fatty, or necrotic cores, all of which provide different
risks of future cardiovascular events [46]. Necrotic cores are
more likely to relate to plaque rupture [33].
Limited studies have shown that the adverse plaque
on CCTA was associated with future cardiovascular events
[47, 48]. Motoyama et al. examined the coronary plaque
features between 38 acute coronary syndrome (ACS) and 33
stable angina pectoris (SAP) patients who underwent CCTA
before percutaneous coronary intervention. In the ACS
group, plaque characteristics with positive remodeling, LAP
with <30HU, or spotty calcification were highly observed
compared to SAP group. Subsequently, they prospectively
investigated the relation of these adverse plaque features to
the future ACS risk among 1059 patients undergoing CCTA
[48] and have demonstrated that subjects with adverse plaque
including both positive remodeling and LAP possessed
almost 23-fold higher risk of future ACS compared to those
without any adverse plaque feature or any plaque. In this
regard, the vulnerability of coronary plaque may be an addi-
tional essential aspect to predict future cardiovascular events.
While being prognostically useful, the utility of aggressive
medical intervention such as coronary revascularization for
these plaque features remains yet unexamined.
8. Risk Stratification for
Asymptomatic Patients
Traditional clinical risk assessment, such as Framingham risk
scores (FRS), has been used universally to stratify the future
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10-year cardiovascular risk among asymptomatic patients.
However, FRS may underestimate the risk. By contrast,
coronary artery calcium (CAC) scanning is a diagnostic tool
to determine the presence and extent of calcified plaque in
coronary arteries by noncontrast CT and an examination for
early detection of CADand improvement of risk stratification
for individuals at low-intermediate or intermediate CAD
risk. A prospective population based study by Greenland
and colleagues [49] explored the relation of FRS and CAC
score (CACS) to future nonfatal MI or cardiac death among
1461 asymptomatic individuals during a median of 7 years
of follow-up. They observed that the FRS + CACS predicted
future nonfatal MI or cardiac death compared to FRS alone
(AUC; 0.68 versus 0.63, 𝑃 < 0.001). A similar result was
reported by another population based MESA study. Yeboah
et al. [50] demonstrated that CACS provided a greater
prognostic value of future cardiac events incorporating
myocardial infarction, angina followed by revascularization,
cardiac arrest, or CHD death compared to FRS alone or FRS
and any other clinical features such as ankle-brachial index,
high-sensitivity CRP, or family history among asymptomatic
individuals with intermediate risk.
Current guidelines do not recommend CACS screening
among asymptomatic patients with low or low-intermediate
risk due to the low absolute event rates [51–53]. However,
several studies demonstrated the high prevalence of CACS
as well as the prognostic impact of CACS among low risk
patients. Nasir et al. explored that increased CAC predicts
higher mortality risk among asymptomatic subjects with
lower number of CAD risk factors [54]. Similar results in
predicting CHD risk were reported by Silverman et al. [55].
Also, these studies demonstrated the high prevalence of
CACS, showing that 30–50% of patients had some CACS
among subjects with CACS zero. In this regard, traditional
risk factors may underestimate the prevalence of coronary
atherosclerotic burden and risk. These previous findings
suggested that CACS is a robust “visualized CAD risk factor”
and its impact is over that of traditional risk factors for
identification, discrimination, and stratification of the risk.
Numerous previous studies investigated the utility of
CACS in predicting all-cause death or cardiovascular events
[56–60]. Budoff et al. investigated the long-term prognostic
value of CACS at a mean follow-up of 7.6 years among
25253 asymptomatic patients and found that CACS provides
incremental information in addition to the total number of
clinical risk factors and age [56]. Also, the 12-year survival
rate in patients with CACS zero is extremely high with 99.4%.
The MESA study has recently collected long-term follow-up
data and will investigate the utility of CACS for not only
mortality but also coronary heart disease (CHD) or coronary
vascular disease (CVD) risks. CACS is calculated by the sum
of coronary calcified plaque lesions with density greater than
or equal to 130Hounsfield units (HU) having an area≥1mm2.
This lesion score is simply measured by the maximal CT
numbers, providing the total CACS by the corrections of all
lesion scores that is associated with the risk. However, it has
not been yet examined whether the volume metric and mor-
phology of CACS are associated with the cardiovascular risk.
More recently, the MESA group explored that the increased
CAC volume is also associated with CHD or CVD. Addi-
tionally, density of CACS is inversely associated with these
risks [61].These newCAC featuresmay be another important
potential metric of CACS for risk reclassification among
asymptomatic patients.
The utility of CCTA to improve the risk stratification over
CACS among asymptomatic subjects is still controversial.
A large multicenter study examined whether CACS was
predictive of future cardiac events compared to CCTA. In the
study of 7590 asymptomatic patients without known CAD,
Cho et al. [62] observed any CCTA findings incorporating
Duke coronary artery disease prognostic index, segment
stenosis score, or segment involvement score as the severity,
extent, and location of CAD by CCTA did not impact on
the incremental prognostic value over models with CACS
and FRS. With respect to these results, the assessment of
only subclinical atherosclerotic burden such as CACS has had
a clinically robust prognostic impact among asymptomatic
patients compared to any other data observed on CCTA, but
that did not incorporate plaque type or vulnerable plaque in
this study. In this regard, the current guideline does not rec-
ommend performing CCTA as a screening purpose among
those subjects presenting no chest symptoms [30]. When
patients possess high clinical CAD risk, however, CCTA
may be considered to be performed for risk assessment.
Min et al. [63] recently investigated the impact of CCTA
for risk discrimination among 400 asymptomatic patients
with diabetes, demonstrating the extent and severity of CAD
by CCTA provided the incremental value to predict MACE
over CACS. The subclinical coronary atherosclerotic burden
determined by CACS provides the independent and incre-
mental prognostic utility in addition to traditional CAD risk
factors among asymptomatic subjects; however, the variables
observed on CCTA such as stenosis severity or extent of
CAD may provide the incremental prognostic value over
CACS alone among those with high risk such as diabetes.
In addition, even when patients had no chest symptom or
atypical chest pain, the previous study demonstrated that
4.3% or 15.5% of patients with intermediate or high FRS had
vulnerable plaque on CCTA, while those with low FRS did
not have any vulnerable plaque [64]. Although no studies
have explored the prognostic impact of vulnerable plaque on
CCTA among asymptomatic population to date, CCTA may
have potential to identify CAD associated with future cardiac
events among those with high FRS risk.
9. Risk Stratification by
Coronary Atherosclerotic Burden for
Symptomatic Patients
The prognostic impact of coronary atherosclerotic burden
defined as CACS for symptomatic patients has been also
reported. In the study examining the relation of CACS and
CCTA findings to MACE including cardiac death, nonfatal
myocardial infarction, or coronary revascularization among
4425 symptomatic subjects reported by Hou and colleagues,
the combined CACS and CCTA findings with stenosis
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severity provided the incremental prognostic information in
predicting MACE over the combination of risk factors and
CACS or the risk factors alone (AUC: 0.92 versus 0.82 versus
0.68) [65].
Although the coronary atherosclerotic burden as deter-
mined by CACS provides the prognostic value among either
asymptomatic or symptomatic subjects, the presence, sever-
ity, and extent of noncalcified plaque are not visualized on
CAC scanning, but that can be identified by CCTA. In a
previous publication by Kristensen and colleagues [45] who
investigated nonculprit nonobstructive coronary plaques on
CCTA in 312 consecutive patients presenting with non-
ST-segment elevation myocardial infarction, nonobstructive
NCP volume was independently and closely associated with
an increase in intermediate-term 16-month cardiac events
(nonobstructive NCP volume (per 100mm3 increase): HR
1.18, 95% CI 1.06–1.31, 𝑃 = 0.002). The volume of nonculprit
and noncalcified plaque may be associated with cardiovas-
cular events. Although the prognostic impact links to not
only calcified plaque volume, but also noncalcified plaque
volume, the metric assessment of plaque volume may be
time consuming. Recently, novel techniques can allow the
measurement of coronary plaque volume observed on CCTA
including calcified and/or noncalcified plaque using semiau-
tomated CT software [66, 67], with high accuracy compared
to IVUS [68]. The relation of the total coronary plaque
volume as determined by the overall coronary atherosclerotic
burden in predicting the future cardiovascular events has
not yet been examined. Further studies could be helpful
to determine whether the overall coronary atherosclerotic
burden observed on CCTA provides incremental prognostic
value in addition to other CCTA information.
10. Risk Stratification by Plaque Progression
Theone-point assessment of coronary atherosclerotic burden
may be limited in predicting future cardiac events since
the presence of coronary plaque accelerates the plaque
progression as well as the risk. At present, the prognostic
utility of coronary plaque progression assessed by CT has
been investigated by several studies [69, 70]. Budoff et al.
have explored the prognostic impact of CACS progression
among 4609 asymptomatic patients who underwent serial
noncontrast cardiac CT [69]. In this study, they observed
that the progression of CACS was significantly associated
with worsening mortality. Subsequently, they also examined
the relation of CACS progression to future CHD among
5682 asymptomatic patients with serial scans from the large
multicenter MESA study with longer follow-up of a median
of 7.6 years and similar results were observed [70]. In these
studies, subjects with positive CACS are likely to experience
the increased mortality or cardiovascular risk. The serial
measurements of CACS may be beneficial, in particular
among patients with high risk such as high baseline CACS.
By contrast, the utility of serial assessment of plaque
progression by CCTAhas not yet been investigated. A limited
study by Lehman et al. examined the utility of serial CCTAs
in assessing the progression of coronary plaque [66]. In this
study of 69 patientswith acute chest pain, the coronary plaque
burden measured by semiautomated CT software signifi-
cantly increased in 2 years and that was associated with
clinical risk factors. With respect to the serial CT studies
using either noncontrast CTor contrast CCTA, the additional
radiation dosemay be a potential issue.However, the required
radiation dose for noncontrast CT is approximately <1–3mSv
[71, 72], which is relatively low. Also, the recent technology
allows decreasing radiation dose for CCTA by the reduction
of tube voltage and/or tube current [72]. In particular, current
high pitch coronary CTA models may be able to provide
radiation dosed within <0.5mSv for CAC scanning [73] and
<1mSv for CCTA [74].
Since the serial assessments by noncontrast cardiac CT
can only provide the development of calcified plaque burden,
it would be of great interest to investigate whether the over-
time change of coronary plaque severity, type, vulnerability
and total plaque volume by serial CCTAs is associated with
future cardiovascular risk.
11. The Future Potential Approach to
Stratify Cardiovascular Risk by CCTA
CCTA has been a robust noninvasive modality to estimate
not only the presence, extent, and severity of CAD, but
also hemodynamic significance of CAD as well as coronary
atherosclerotic plaque characteristics or burden. For a higher
diagnostic performance of CCTA, the combined approach
by both anatomical and hemodynamic assessments might
be useful, since this approach improves false positive rates
provided by the anatomical assessment alone because of the
overestimation of coronary stenosis. While being diagnosti-
cally useful, a potential for risk stratification by the combined
assessment is still unclear.
Several previous studies demonstrated the incremental
prognostic value of anatomic and hemodynamic assessment
of CAD by CCTA and SPECT to date [75, 76]. Pazhenkottil
and colleagues examined the prognostic value of hybrid
CCTA/SPECT study among 302 subjects with suspected
CAD [75]. In this study, the patients with abnormal perfusion
SPECT and CAD with ≥50% or those with either abnor-
mality experienced higher MACE (all-cause death, nonfatal
MI, unstable angina requiring hospitalization, and coro-
nary revascularization), or death, or myocardial infarction
when compared to those without any abnormality. Another
study by Kawai et al. examined the utility of the combined
assessment with CCTA and SPECT among 204 patients
who underwent coronary artery bypass grafting [76]. They
observed the combination between unprotected coronary
territories defined by the number of significant stenoses with
left main ≥50%, other native coronary artery stenoses ≥70%,
or graft stenosis ≥70% by CCTA and summed stress score
by SPECT improved the prediction of cardiovascular events
incorporating cardiac death, nonfatal myocardial infarction,
unstable angina requiring revascularization, and heart failure
hospitalization. The combination of anatomical assessment
and hemodynamic assessment of CAD could provide incre-
mental prognostic value.
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There were only a few studies demonstrating the com-
bined evaluation of coronary plaque characteristics and other
CAD features to predict cardiovascular risk [3, 9]. In the
PROSPECT study by Stone et al. [3] who investigated the
natural history of coronary plaque by IVUS and the risk
among 697 patients with acute coronary syndromes who
underwent ICA, they observed the presence of≥70% stenosis,
TCFA and minimum luminal area <4mm2 showed 5.03,
3.35, and 3.21-fold increased future major adverse cardio-
vascular events (MACE). When combining all features, the
MACE risk increased 11-fold higher compared to that of
CAD without these plaque features. The finding suggested
that all plaque characteristics including the severity, burden,
and vulnerability of coronary plaque were associated with
MACE risk and this combination predicted the greatest
MACE risk. Another study by van Werkhoven et al. [9]
has investigated the prognostic value of CCTA and SPECT
among 541 subjects with suspected CAD.They observed that
the combined clinical characteristics, abnormal myocardial
perfusion by SPECT, stenosis severity ≥50% by CCTA,
and the presence of noncalcified plaque by CCTA showed
the greatest incremental prognostic value when compared
to clinical characteristics alone, clinical + stenosis severity
≥50%, clinical + abnormal perfusion, or clinical + abnormal
perfusion + stenosis severity ≥50%, a finding that suggested
the combination of anatomical, hemodynamic significant
CAD and plaque type may be a greater potential for risk
stratification.
Since cardiac death or myocardial infarction occurs
because ofmultifactorial interaction, the single approachmay
be limited to identify CAD associated with the future cardiac
events. It would be of great interest to take into account all
available information such as anatomical and hemodynamic
significance of CAD as well as coronary atherosclerosis
incorporating the burden, type, and vulnerability for the
risk stratification and the guide in the medical management
among subjects with suspected CAD. However, these vari-
ablesmay be excessive information for patientswith lowCVD
risk.The appropriate selection in identifying individuals who
are at high risk of future cardiac events should be carefully
considered based on chest symptoms (asymptomatic versus
symptomatic), CAD risk factors including FRS, or the history
of known/unknown CAD. Although CACS has been a robust
prognostic tool among asymptomatic patients, the utility of
CACSmay be extended to those with a low risk.With respect
to those with a high risk of CAD such as diabetes or high
FRS, CCTA may be a potential for risk stratification. By
contrast,more detailed information regardingCADobserved
on CCTA would be needed for risk stratification among
patients with high risk of CAD such as symptomatic, high
FRS, or history of known CAD. Given the novel method to
assess functional significance of CAD by CCTA, the relation
of this new approach to CVD risk has not been examined
to date. However, the hybrid assessment by CCTA including
anatomical and hemodynamic information, coronary plaque
characteristics, and atherosclerotic burdenmay have a poten-
tial role in stratifying CVD risk.
12. Conclusion
CCTA is the only robust noninvasivemodality to evaluate the
presence and extent of CAD, anatomical and hemodynamic
severity of CAD, coronary plaque characteristics—type and
vulnerability—and the atherosclerotic burden. With taking
advantage of these CCTA abilities, all available data of CAD
observed on CCTA may improve identification, discrimina-
tion, and reclassification of the future cardiovascular risk.
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